ABBOTT LABORATORIES— Sankey Diagram
Quarterly mode · period ending 2026-03-31 · SEC EDGAR
ComparingFY2026 (Q4) vs FY2025 (Q4)
Revenue
$11.16B
↑+7.8% +$806Mvs FY2025 (Q4)
Gross Profit
$6.27B
↑+6.5% +$384Mvs FY2025 (Q4)
Operating Income
$1.34B
↓-20.6% -$348Mvs FY2025 (Q4)
Net Income
$1.08B
↓-18.7% -$248Mvs FY2025 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2026 (Q4) | FY2025 (Q4) |
|---|---|---|
| Revenue | $11.16B | $10.36B |
| COGS | $4.89B | $4.47B |
| Gross Profit | $6.27B | $5.89B |
| R&D | $767M | $716M |
| SG&A | $3.74B | $3.06B |
| D&A | $381M | $336M |
| Other OpEx | $41M | $84M |
| Operating Income | $1.34B | $1.69B |
| Interest Exp. | $174M | $131M |
| Other Non-Op | $0 | $0 |
| Pretax Income | $1.17B | $1.56B |
| Tax | $94M | $237M |
| Net Income | $1.08B | $1.32B |
QuarterCharts · SEC EDGAR data · ABT · Comparing FY2026 (Q4) vs FY2025 (Q4)